The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Polyvalent vaccine-KLH conjugate and OPT-821 with bevacizumab (BEV) in patients with ovarian cancer in second or greater remission.
Roisin Eilish O'Cearbhaill
No relevant relationships to disclose
Alexia Iasonos
No relevant relationships to disclose
Qin Zhou
No relevant relationships to disclose
Robert Durany
No relevant relationships to disclose
Carol Aghajanian
No relevant relationships to disclose
Martee Leigh Hensley
No relevant relationships to disclose
Jason A. Konner
No relevant relationships to disclose
Vicky Makker
No relevant relationships to disclose
William P. Tew
No relevant relationships to disclose
Martin Fleisher
No relevant relationships to disclose
Paul Sabbatini
No relevant relationships to disclose